10.6084/M9.FIGSHARE.C.6280133.V1
Andrea Schwarz
Andrea
Schwarz
Charité - University Medicine Berlin
Ilja Demuth
Ilja
Demuth
Berlin Institute of Health at Charité - Universitätsmedizin Berlin
Berlin-Brandenburger Centrum für Regenerative Therapien
Charité - University Medicine Berlin
Ulf Landmesser
Ulf
Landmesser
German Centre for Cardiovascular Research
Berlin Institute of Health at Charité - Universitätsmedizin Berlin
Charité - University Medicine Berlin
Arash Haghikia
Arash
Haghikia
German Centre for Cardiovascular Research
Berlin Institute of Health at Charité - Universitätsmedizin Berlin
Charité - University Medicine Berlin
Maximilian König
Maximilian
König
Charité - University Medicine Berlin
Elisabeth Steinhagen-Thiessen
Elisabeth
Steinhagen-Thiessen
University of Rostock
Charité - University Medicine Berlin
Low-density lipoprotein cholesterol goal attainment in patients with clinical evidence of familial hypercholesterolemia and elevated Lp(a)
Abstract Background Although potent lipid-lowering therapies are available, patients commonly fall short of recommended low-density lipoprotein cholesterol (LDL-C) levels. The aim of this study was to examine the relationship between familial hypercholesterolemia (FH) and elevated lipoprotein(a) [Lp(a)] and LDL-C goal attainment, as well as the prevalence and severity of coronary artery disease (CAD). Moreover, we characterized patients failing to meet recommended LDL-C goals. Methods We performed a cross-sectional analysis in a cohort of patients undergoing cardiac catheterization. Clinical FH was determined by the Dutch Clinical Lipid Network Score, and Lp(a) ≥ 50 mg/dL (≈ 107 nmol/L) was considered elevated. Results A total of 838 participants were included. Overall, the prevalence of CAD was 72%, and 62% received lipid-lowering treatment. The prevalence of clinical FH (probable and definite FH) was 4%, and 19% had elevated Lp(a) levels. With 35%, LDL-C goal attainment was generally poor. Among the participants with clinical FH, none reached their LDL-C target. Among patients with elevated Lp(a), LDL-C target achievement was only 28%. The prevalence and severity of CAD were higher in participants with clinical FH (86% prevalence) and elevated Lp(a) (80% prevalence). Conclusion Most participants failed to meet their individual LDL-C goals according to the ESC 2016 and 2019 guidelines. In particular, high-risk patients with clinical FH or elevated Lp(a) rarely met their target for LDL-C. The identification of these patients and more intense treatment approaches are crucial for the improvement of CAD primary and secondary prevention.
Medicine
Pharmacology
59999 Environmental Sciences not elsewhere classified
Immunology
60506 Virology
figshare
2022
2022-11-03
2022-11-03
Collection
10.1186/s12944-022-01708-9
10.6084/m9.figshare.c.6280133
CC BY 4.0